Amgen Licenses ImmunoGen Tech, Hemispherx Drug Questioned by FDA: Healthcare Business Recap
North Carolina Governor Beverly Perdue is expected to announce in Forsyth County on Wednesday that Herbalife (NYSE:HLF) will bring some 500 jobs along with a $100 million manufacturing and distribution hub to Winston-Salem, according to several inside sources to the company.
On Wednesday, ImmunoGen (NASDAQ:IMGN) reported that Amgen (NASDAQ:AMGN) has licensed the exclusive right to use its maytansinoid TAP tech for the development of anticancer therapeutics to a third target whose identity is undivulged. In 2009, Amgen licensed rights for two other targets and has two compounds in clinical testing under those licenses. ImmunoGen is a biotechnology firm that develops anticancer therapeutics using its Targeted Antibody Payload tech and antibody expertise.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.
Subsequent to the FDA mandating that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) place a warning connected to fatal and non-fatal serious skin reactions on the boxes that contain its Incivek HCV treatment, Piper Jaffray said that it anticipates that sales of the drug could decline further. The analyst keeps its Neutral on the stock for the present time.
In a preliminary review of Hemispherx Biopharma’s (AMEX:HEB) Ampligen for the treatment of chronic fatigue syndrome on Tuesday, the FDA questioned the drug’s safety and effectiveness. The medication has been in development in excess of two decades and the FDA’s arthritis drugs advisory panel will review it on Thursday.
Investing Insights: Is This Healthcare Company an Outperform?